Clarke S E
Department of Nuclear Medicine, Guy's Hospital, London, United Kingdom.
J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):323-6.
[131I]Metaiodobenzylguanidine (131I-MIBG) was utilized in the therapy of seven patients with medullary thyroid cancer. Treatment doses ranged from 3.7 to 11 GBq, for upto four total treatments. Six of the seven patients treated showed some response to treatment (from transient partial response to symptom palliation). Treatment was tolerated well in all patients, with minimal side-effects and no signs of hematologic radiotoxicity. These encouraging results emphasize the potential of 131I-MIBG as a form of targetted radiometabolic therapy in patients with medullary thyroid cancer.
[131I]间碘苄胍（131I-MIBG）被用于治疗7例甲状腺髓样癌患者。治疗剂量为3.7至11GBq，总共进行了多达4次治疗。接受治疗的7例患者中有6例对治疗有一定反应（从短暂的部分缓解到症状减轻）。所有患者对治疗耐受性良好，副作用极小，且无血液学放射性毒性迹象。这些令人鼓舞的结果强调了131I-MIBG作为甲状腺髓样癌患者靶向放射代谢治疗形式的潜力。
